英国学术主导临床试验中的电子知情同意:当前实践、挑战与更多证据的需求
2021年4月至6月对英国53家UKCRC注册临床试验单位开展调查,34家(64%)回应,其中21家(62%)已在至少一项试验中实施电子知情同意,涵盖CTIMP、ATIMP和非CTIMP等类型。随后举办两场研讨会,197名参会者参与讨论。作者认为电子知情同意在学术主导试验中应用日益增多,但试验者、患者和公众仍存在不确定性,缺乏正式实用指南和证据,强烈鼓励试验者继续分享实施经验。
要点
- 34家(64%)回应单位中21家(62%)已在至少一项试验中实施电子知情同意。
- 实施范围涵盖CTIMP、ATIMP和非CTIMP等不同类型试验。
- 两场研讨会共197名参会者,讨论指出缺乏正式实用指南和证据。
核心结论
- 电子知情同意在学术主导试验中应用日益增多,但试验者、患者和公众仍存在不确定性,包括缺乏正式实用指南和证明最佳或合适方法的证据。
- 作者强烈鼓励试验者继续分享各自实施电子知情同意的经验。
研究设计与样本
- 2021年4月至6月对UKCRC注册临床试验单位开展调查,了解电子知情同意的实施情况、观点及系统程序员和质量保证人员的经验。
- 未使用电子知情同意的临床试验单位被要求提供原因/障碍(包括无合适试验)及未来实施计划。
- 随后举办两场面向试验者及患者和公众参与代表的活动,以传播发现、促进讨论、分享经验并识别学术临床试验单位社区认为需要更多研究的领域。
主要发现
- 53家临床试验单位中34家(64%)回应调查,在英国地理分布良好。
- 回应的临床试验单位中21家(62%)已在至少一项试验中实施电子知情同意,涵盖CTIMP、ATIMP和非CTIMP等不同类型试验。
- 两场研讨会共197名参会者参与广泛讨论。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During the COVID-19 pandemic, in-person healthcare visits were reduced. Consequently, trial teams needed to consider implementing remote methods for conducting clinical trials, including e-Consent. Although some clinical trials may have implemented e-Consent prior to the pandemic, anecdotes of uptake for this method increased within academic-led trials. When the increased use of this process emerged, representatives from several large academic clinical trial groups within the UK collaborated to discuss ways in which trialists can learn from one another when implementing e-Consent. METHODS: A survey of UKCRC-registered Clinical Trials Units (CTUs) was undertaken in April-June 2021 to understand the implementation of and their views on the use of e-Consent and experiences from the perspectives of systems programmers and quality assurance staff on the use of e-Consent. CTUs not using e-Consent were asked to provide any reasons/barriers (including no suitable trials) and any plans for implementing it in the future. Two events for trialists and patient and public involvement (PPI) representatives were then held to disseminate findings, foster discussion, share experiences and aid in the identification of areas that the academic CTU community felt required more research. RESULTS: Thirty-four (64%) of 53 CTUs responded to the survey, with good geographical representation across the UK. Twenty-one (62%) of the responding CTUs had implemented e-Consent in at least one of their trials, across different types of trials, including CTIMPs (Clinical Trial of Investigational Medicinal Product), ATIMPs (Advanced Therapy Medicinal Products) and non-CTIMPs. One hundred ninety-seven participants attended the two workshops for wide-ranging discussions. CONCLUSION: e-Consent is increasingly used in academic-led trials, yet uncertainties remain amongst trialists, patients and members of the public. Uncertainties include a lack of formal, practical guidance and a lack of evidence to demonstrate optimal or appropriate methods to use. We strongly encourage trialists to continue to share their own experiences of the implementation of e-Consent.
引用
- Mitchell EJ, Appelbe D, Bravery A, et al. e-Consent in UK academic-led clinical trials: current practice, challenges and the need for more evidence. Trials. 2023. PMID: 37817277. doi:10.1186/s13063-023-07656-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。